NASDAQ : ALDX
Aldeyra Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.5603 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 33.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 8.44M | 9.60M | 11.89M | 13.34M | 15.37M | 11.28M |
| Research & Development | 15.63M | 25.66M | 48.22M | 29.46M | 47.31M | 44.94M |
| Operating Expenses | 24.07M | 35.27M | 60.12M | 42.79M | 62.68M | 56.22M |
| Operating Income | -24.07M | -35.27M | -60.12M | -42.79M | -62.68M | -56.22M |
| Interest Expense | -1.42M | -1.91M | -1.93M | -2.07M | -1.69M | -1.74M |
| Interest & Investment Income | 2.43M | 3.32M | 6.19M | 7.32M | 2.35M | 185.36K |
| EBT Excluding Unusual Items | -23.05M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
| Pretax Income | -23.05M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
| Net Income | -23.05M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
| Net Income to Common | -23.05M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
| Shares Outstanding (Basic) | 60.23M | 60.06M | 59.48M | 58.94M | 58.41M | 54.04M |
| Shares Outstanding (Diluted) | 60.23M | 60.06M | 59.48M | 58.94M | 58.41M | 54.04M |
| EPS (Basic) | -0.38 | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 |
| EPS (Diluted) | -0.38 | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 |
| Free Cash Flow | -22.04M | -33.35M | -43.21M | -30.33M | -56.65M | -42.56M |
| Free Cash Flow Per Share | -0.37 | -0.56 | -0.73 | -0.51 | -0.97 | -0.79 |
| EBITDA | -23.80M | -35.01M | -59.87M | -42.53M | -62.42M | -55.96M |
| D&A For EBITDA | 266.10K | 251.99K | 249.62K | 262.78K | 258.71K | 264.18K |
| EBIT | -24.07M | -35.27M | -60.12M | -42.79M | -62.68M | -56.22M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 45.09M | 70.04M | 54.53M | 142.82M | 144.42M | 104.79M |
| Short-Term Investments | 46.62M | 29.88M | ||||
| Cash & Short-Term Investments | 45.09M | 70.04M | 101.15M | 142.82M | 174.30M | 104.79M |
| Other Receivables | 3.24M | 28.77K | ||||
| Receivables | 3.24M | 125.03M | ||||
| Prepaid Expenses | 1.66M | 699.12K | 709.24K | 523.53K | 874.95K | 528.87K |
| Other Current Assets | 628.66K | 1.04M | 2.21M | 4.46M | 2.61M | 2.40M |
| Total Current Assets | 47.38M | 71.78M | 104.07M | 147.81M | 181.02M | 232.75M |
| Property, Plant & Equipment | 161.65K | 275.86K | 266.95K | 516.58K | 268.54K | 384.35K |
| Long-Term Deferred Charges | 267.26K | |||||
| Total Assets | 47.54M | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M |
| Accounts Payable | 137.48K | 158.46K | 180.45K | 1.34M | 133.62K | 1.02M |
| Accrued Expenses | 3.37M | 6.12M | 12.12M | 5.54M | 14.07M | 10.52M |
| Current Portion of Long-Term Debt | 15.25M | 31.37K | 15.15M | 911.76K | ||
| Current Portion of Leases | 143.45K | 280.54K | 271.63K | 239.18K | 249.26K | 229.61K |
| Current Unearned Revenue | 6.00M | 6.00M | 6.00M | |||
| Total Current Liabilities | 9.66M | 27.81M | 18.60M | 22.26M | 15.36M | 11.77M |
| Long-Term Debt | 15.00M | 14.92M | 15.50M | |||
| Long-Term Leases | 271.63K | 125.23K | ||||
| Long-Term Unearned Revenue | 6.00M | |||||
| Total Liabilities | 9.66M | 27.81M | 33.60M | 28.53M | 30.28M | 27.40M |
| Common Stock | 60.32K | 60.16K | 59.65K | 59.20K | 58.56K | 58.08K |
| Additional Paid-In Capital | 530.69M | 528.15M | 521.02M | 513.99M | 507.77M | 500.37M |
| Retained Earnings | -492.86M | -483.96M | -450.11M | -394.26M | -356.72M | -294.69M |
| Comprehensive Income & Other | 37.44K | -103.94K | ||||
| Shareholders' Equity | 37.89M | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M |
| Total Liabilities & Equity | 47.54M | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M |
| Total Debt | 143.45K | 15.53M | 15.30M | 15.66M | 16.08M | 15.86M |
| Net Cash (Debt) | 44.95M | 54.51M | 85.85M | 127.17M | 158.22M | 88.93M |
| Net Cash Per Share | 0.75 | 0.91 | 1.44 | 2.16 | 2.71 | 1.65 |
| Filing Date Shares Outstanding | 60.33M | 60.18M | 59.71M | 58.90M | 58.58M | 58.10M |
| Total Common Shares Outstanding | 60.32M | 60.16M | 59.65M | 59.20M | 58.56M | 58.08M |
| Working Capital | 37.72M | 43.97M | 85.47M | 125.55M | 165.66M | 220.98M |
| Book Value Per Share | 0.63 | 0.74 | 1.19 | 2.02 | 2.58 | 3.54 |
| Tangible Book Value | 37.89M | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M |
| Tangible Book Value Per Share | 0.63 | 0.74 | 1.19 | 2.02 | 2.58 | 3.54 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -23.05M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
| Depreciation & Amortization | 266.10K | 251.99K | 249.62K | 262.78K | 258.71K | 264.18K |
| Other Amortization | 267.26K | |||||
| Loss (Gain) From Sale of Investments | -310.63K | -1.15M | -1.67M | -14.54K | -47.24K | |
| Stock-Based Compensation | 4.33M | 6.09M | 7.97M | 5.75M | 8.29M | 7.11M |
| Other Operating Activities | 151.10K | 218.26K | 177.33K | 354.19K | 331.15K | 409.47K |
| Change in Accounts Payable | -892.05K | -21.99K | -1.16M | 1.20M | -886.08K | 638.06K |
| Change in Unearned Revenue | 6.00M | |||||
| Change in Other Net Operating Assets | -2.51M | -5.16M | 7.07M | -6.34M | -2.56M | 6.80M |
| Operating Cash Flow | -22.02M | -33.35M | -43.21M | -30.33M | -56.64M | -42.56M |
| Capital Expenditures | -23.10K | -16.32K | -7.81K | |||
| Investment in Securities | 41.00M | 47.74M | -44.92M | 30.00M | -29.94M | |
| Investing Cash Flow | 40.98M | 47.74M | -44.92M | 30.00M | -29.95M | -7.81K |
| Long-Term Debt Repaid | -292.50K | -1.04M | ||||
| Net Debt Issued (Repaid) | -15.30M | -292.50K | -1.04M | |||
| Issuance of Common Stock | 191.89K | 1.12M | 388.34K | 305.23K | 1.22M | 194.50M |
| Repurchase of Common Stock | -532.95K | |||||
| Other Financing Activities | -267.26K | |||||
| Financing Cash Flow | -15.11M | 1.12M | -171.42K | -1.27M | 1.22M | 194.50M |
| Net Cash Flow | 3.85M | 15.51M | -88.30M | -1.60M | -85.37M | 151.93M |
| Free Cash Flow | -22.04M | -33.35M | -43.21M | -30.33M | -56.65M | -42.56M |
| Free Cash Flow Per Share | -0.37 | -0.56 | -0.73 | -0.51 | -0.97 | -0.79 |
| Levered Free Cash Flow | -15.62M | -21.46M | -17.06M | -27.62M | 92.19M | -123.60M |
| Unlevered Free Cash Flow | -14.73M | -20.27M | -15.86M | -26.32M | 93.25M | -122.51M |
| Cash Interest Paid | 1.41M | 1.69M | 1.75M | 1.70M | 1.34M | 1.34M |
| Change in Working Capital | -3.40M | -5.18M | 5.91M | 861.18K | -3.44M | 7.44M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 33.80M | 311.64M | 297.15M | 206.47M | 407.58M | 232.37M |
| Enterprise Value | -11.15M | 251.89M | 240.02M | 79.31M | 259.69M | 131.83M |
| Last Close Price | 0.56 | 5.18 | 4.99 | 3.51 | 6.96 | 4.00 |
| Forward PE | 16.32 | 13.27 | ||||
| PB Ratio | 0.89 | 7.04 | 4.18 | 1.72 | 2.70 | 1.13 |
| P/TBV Ratio | 0.89 | 7.04 | 4.18 | 1.72 | 2.70 | 1.13 |
| Debt / Equity Ratio | 0.00 | 0.35 | 0.22 | 0.13 | 0.11 | 0.08 |
| Net Debt / Equity Ratio | -1.19 | -1.23 | -1.21 | -1.06 | -1.05 | -0.43 |
| Net Debt / EBITDA Ratio | 1.89 | 1.56 | 1.43 | 2.99 | 2.54 | 1.59 |
| Net Debt / FCF Ratio | 2.04 | 1.64 | 1.99 | 4.19 | 2.79 | 2.09 |
| Quick Ratio | 4.67 | 2.52 | 5.44 | 6.42 | 11.56 | 8.90 |
| Current Ratio | 4.91 | 2.58 | 5.59 | 6.64 | 11.79 | 19.77 |
| Return on Equity (ROE) | -49.48% | -58.73% | -58.54% | -27.73% | -34.77% | -43.56% |
| Return on Assets (ROA) | -22.70% | -24.95% | -29.71% | -16.23% | -18.91% | -22.20% |
| Return on Capital Employed (ROCE) | -63.50% | -79.70% | -69.90% | -33.90% | -37.80% | -25.40% |
| Earnings Yield | -68.31% | -10.86% | -18.80% | -18.18% | -15.22% | -24.86% |
| FCF Yield | -65.22% | -10.70% | -14.54% | -14.69% | -13.90% | -18.32% |
| Buyback Yield / Dilution | -0.79% | -0.96% | -0.92% | -0.92% | -8.08% | -59.11% |